RemeGen Company Description

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers.

It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors.

The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.

RemeGen Co., Ltd.

Country	China
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	2,999
CEO	Jianmin Fang

Contact Details

Address: 58 Middle Beijing Road Yantai China
Phone	86 53 5611 3511
Website	remegen.com

Stock Details

Ticker Symbol	9995
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000048G6
SIC Code	2836

Key Executives

Name	Position
Dr. Jianmin Fang	Co-Founder, Chief Executive Officer, GM, Member of Scientific Advisory Board and Executive Director
Weidong Wang	Co-Founder and Executive Chairman
Shaojing Tong	Chief Financial Officer and Joint Company Secretary
Jian Lin	Executive Director
Qingkai Wen	Executive Director and Board Secretary
Kaisheng Huang	Chief Operating Officer
Dr. Marie Zhu	Chief Technical Officer
Dr. Zhulun Wang	Chief Scientific Officer
Dr. Xiaoming Yang Ph.D.	Chief Manufacturing Officer